320 related articles for article (PubMed ID: 9425933)
1. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
2. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
4. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
[TBL] [Abstract][Full Text] [Related]
5. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
Nakagawa M; Colombo C; Setchell KD
Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
[TBL] [Abstract][Full Text] [Related]
7. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
9. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
[TBL] [Abstract][Full Text] [Related]
10. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans.
Marschall HU; Matern H; Wietholtz H; Egestad B; Matern S; Sjövall J
J Clin Invest; 1992 Jun; 89(6):1981-7. PubMed ID: 1602004
[TBL] [Abstract][Full Text] [Related]
11. Liver disease in cystic fibrosis.
Colombo C; Apostolo MG; Assaisso M; Roman B; Bottani P
Neth J Med; 1992 Oct; 41(3-4):119-22. PubMed ID: 1470280
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
13. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
14. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis.
Marschall HU; Broomé U; Einarsson C; Alvelius G; Thomas HG; Matern S
J Lipid Res; 2001 May; 42(5):735-42. PubMed ID: 11352980
[TBL] [Abstract][Full Text] [Related]
15. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children.
Lykavieris P; Ducot B; Lachaux A; Dabadie A; Broué P; Sarles J; Bernard O; Jacquemin E
J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):623-9. PubMed ID: 18955864
[TBL] [Abstract][Full Text] [Related]
16. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
17. Studies of serum and feces bile acids determination by gas chromatography-mass spectrometry.
Tadano T; Kanoh M; Matsumoto M; Sakamoto K; Kamano T
Rinsho Byori; 2006 Feb; 54(2):103-10. PubMed ID: 16548228
[TBL] [Abstract][Full Text] [Related]
18. Modulation of steady-state messenger RNA levels in the regenerating rat liver with bile acid feeding.
Kren BT; Rodrigues CM; Setchell KD; Steer CJ
Liver Transpl; 2001 Apr; 7(4):321-34. PubMed ID: 11303292
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of bile acids in the feces of colorectal cancer patients by gas chromatography-mass spectrometry (GC-MS).
Tadano T; Kanoh M; Kondoh H; Matsumoto M; Mimura K; Kanoh Y; Sakamoto K; Kamano T
Rinsho Byori; 2007 May; 55(5):417-27. PubMed ID: 17593686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
